Chengdu Olymvax Biopharmaceuticals, Inc. (688319.SH) Latest Company News

Oct 29, 2026, 11:37 UTC
Oulin Bio reported first-three-quarter 2026 revenue of 599 million yuan, up 18.15% year over year, and a net loss attributable to shareholders of 6.8016 million yuan, compared with a profit a year earlier.
Source:
- finance.sina.cn
Oct 29, 2026, 11:37 UTC
Oulin Bio reported third-quarter 2026 revenue of 238 million yuan, up 18.17% year over year, and net profit attributable to shareholders of 26.0709 million yuan, down 23.95%.
Source:
- finance.sina.cn
Oct 19, 2026, 11:54 UTC
Oulin Biopharma said it received the Phase III clinical study summary report for its recombinant Staphylococcus aureus vaccine, which showed 73.25% protective efficacy against infection within 42 days after closed-fracture surgery.
Source:
- finance.sina.cn
Aug 31, 2026, 14:42 UTC
On August 31, 2026, ten A-share listed companies including Olymvax Biopharmaceuticals, Xiaocheng Technology, Hengyin Technology, Xinhongye, Feirongda, Ruison Technology, Weiteng Electric, Jinge New Materials, Baling Oriental, and Bestore disclosed plans to reduce their holdings, while ST Kaili and XCMG disclosed plans to increase holdings.
Source:
- finance.sina.cn
Aug 31, 2026, 13:11 UTC
Olymvax Biopharmaceuticals director and deputy general manager Chen Aimin plans to reduce his shareholding in the company by up to 0.0338% of total shares.
Source:
- finance.sina.cn
Aug 17, 2026, 11:16 UTC
Olymvax Biopharmaceuticals reported a net loss of 32.8726 million yuan for the first half of 2026, turning from a profit of 13.1969 million yuan a year earlier, with revenue of 361 million yuan, up 18.14% year-on-year.
Source:
- finance.sina.cn

688319.SH

Oulin Bio reported first-three-quarter 2026 revenue of 599 million yuan, up 18.15% year over year, and a net loss attributable to shareholders of 6.8016 million yuan, compared with a profit a year earlier.

Oulin Bio reported third-quarter 2026 revenue of 238 million yuan, up 18.17% year over year, and net profit attributable to shareholders of 26.0709 million yuan, down 23.95%.

Oulin Biopharma said it received the Phase III clinical study summary report for its recombinant Staphylococcus aureus vaccine, which showed 73.25% protective efficacy against infection within 42 days after closed-fracture surgery.

Olymvax Biopharmaceuticals director and deputy general manager Chen Aimin plans to reduce his shareholding in the company by up to 0.0338% of total shares.

Olymvax Biopharmaceuticals reported a net loss of 32.8726 million yuan for the first half of 2026, turning from a profit of 13.1969 million yuan a year earlier, with revenue of 361 million yuan, up 18.14% year-on-year.